NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including upcoming milestones at the JPMorgan Small Cap Conference in Boston. Mr. Weiss’ presentation will take place tomorrow, Tuesday, November 1, 2005 at 11:30 a.m. Eastern Time in the Phillips Room of the Four Seasons Hotel. A live audio webcast of Mr. Weiss’ presentation will be available at http://equityconferences.jpmorgan.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx’s lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life- threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in- licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Ron Bentsur VP, Finance & Investor Relations 212 531-5965 ron@keryx.com
Keryx Biopharmaceuticals, Inc.
CONTACT: Ron Bentsur, VP, Finance & Investor Relations, +1-212-531-5965,ron@keryx.com
